Pirisudanol
The topic of Pirisudanol is one that has generated great interest in today's society. It is an issue that affects us all in one way or another, whether directly or indirectly. Without a doubt, it is a topic that has generated conflicting opinions and has been the subject of numerous debates. In this article, we will analyze Pirisudanol in detail and its implications in our daily life. We will explore different perspectives and seek to better understand this issue that concerns us so much.
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.046.887 |
| Chemical and physical data | |
| Formula | C16H24N2O6 |
| Molar mass | 340.376 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pirisudanol (Mentis, Menthen, Mentium, Nadex, Nadexen, Nadexon, Pridana, Stivane), also known as pyrisuccideanol, is the succinic acid ester of pyridoxine (a form of vitamin B6) and of deanol (DMAE).[1] It has been used in Europe in the treatment of mild cognitive impairment as well as fatigue and depression.[1][2][3][4][5]
Synthesis
Pirisudanol is synthesized by the following method:[6][7]
Cyclic ketal formation between pyridoxine HCl: (1) and acetone resulted in alpha4,3-O-Isopropylidene Pyridoxine (2). In the other arm of the synthesis succinic anhydride (3) is then esterified with Deanol (4) gives Yakton (5). Halogenation of the remaining carboxyl group with thionyl chloride gives PC135056269 (6). In a convergent synthesis, esterification between 2 and 6 gives 7. The last step consists of deblocking the protecting group by hydrolysis with 1% formic acid in ethanol to give the product (8).
Analytical data
(uv, ir, pmr, ms):[8]
See also
References
- ^ a b "Psycho-Babble Medication Thread 69493".
- ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ^ Bathien N, Willer JC, Hugelin A (1976). "". L'Encéphale (in French). 2 (1): 55–60. PMID 1261486.
- ^ Murphy JE (1981). "An evaluation of pyrisuccideanol maleate (Nadex) in the treatment of mild to moderate depression in patients aged 55 years and over, presenting in general practice". The Journal of International Medical Research. 9 (5): 330–7. doi:10.1177/030006058100900506. PMID 7297757. S2CID 30526982.
- ^ Zmorski T (September 1983). "". Therapeutische Umschau. Revue Thérapeutique (in German). 40 (9): 817–20. PMID 6138876.
- ^ Andre Paris Esanu, DE2102831B2 (1975 to Societe D'etudes De Produits, Chimiques, Issy-Les-Moulineaux (Frankreich)).
- ^ Andre Esanu, GB1447338 (1976 to Soc D Etudes Prod Chimique).
- ^ Gielsdorf, W.; Klug, E. (1983). "Zur Analytik und renalem Ausscheidungsverhalten von Pirisudanol (Stivane)". Zeitschrift für Rechtsmedizin. 90 (3): 229–238. doi:10.1007/BF02116234. ISSN 0044-3433.